Zydus Lifesciences has confirmed that members of its promoter group and persons in control of the company intend to participate in the previously announced INR 1,100 crore share buyback. The buyback, which targets up to 95,65,217 equity shares at a price of INR 1,150 per share, will be executed via the tender offer route. This move signals confidence from the company’s leadership regarding the buyback initiative.
Commitment to Capital Allocation
Following the Board of Directors’ recent approval, Zydus Lifesciences has provided further clarity on its capital return strategy. On May 19, 2026, the company announced that the promoter group and individuals in control have formally communicated their intention to participate in the upcoming buyback of equity shares.
Buyback Details
The company is set to repurchase up to 95,65,217 fully paid-up equity shares. The buyback is priced at INR 1,150 per share, representing an aggregate investment of up to INR 1,100 crore. This buyback constitutes approximately 0.95% of the company’s total paid-up equity share capital.
Execution Strategy
The process will be conducted on a proportionate basis through the tender offer route. Participating promoters and those in control of the company have committed to tendering their shares up to their respective shareholding limits or lower, as permitted by existing legal frameworks. This development marks a significant step in the company’s efforts to return value to its shareholders.
Source: BSE
